AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 165 filers reported holding AKERO THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,178,024 | -58.8% | 102,420 | -61.9% | 0.00% | -50.0% |
| Q2 2023 | $12,553,685 | +15.7% | 268,917 | -5.1% | 0.00% | 0.0% |
| Q1 2023 | $10,846,863 | +68012.2% | 283,516 | -2.4% | 0.00% | -20.0% |
| Q4 2022 | $15,925 | -99.8% | 290,606 | -0.3% | 0.01% | +25.0% |
| Q3 2022 | $9,917,000 | +189.8% | 291,391 | -19.5% | 0.00% | +300.0% |
| Q2 2022 | $3,422,000 | -28.6% | 361,988 | +7.2% | 0.00% | 0.0% |
| Q1 2022 | $4,794,000 | -10.2% | 337,790 | +33.9% | 0.00% | -50.0% |
| Q4 2021 | $5,336,000 | +13.6% | 252,265 | +20.0% | 0.00% | 0.0% |
| Q3 2021 | $4,699,000 | -11.9% | 210,246 | -2.2% | 0.00% | 0.0% |
| Q2 2021 | $5,336,000 | +462.9% | 215,062 | +557.8% | 0.00% | – |
| Q1 2021 | $948,000 | -25.5% | 32,694 | -33.7% | 0.00% | – |
| Q4 2020 | $1,273,000 | – | 49,334 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |